This inventor holds 3 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignee: Japan Tobacco Inc.. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Innovations of Yoshifumi Ueda
Introduction
Yoshifumi Ueda is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing therapeutic agents for various medical conditions. With a total of two patents to his name, Ueda's work focuses on innovative solutions for nephrotic syndrome and pain management.
Latest Patents
Ueda's latest patents include a therapeutic or preventive agent for nephrotic syndrome, which features an indole compound. This invention provides a novel approach to treating nephrotic syndrome by utilizing N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically acceptable salt thereof. Additionally, he has developed a method for treating pain or interstitial cystitis using the same indole compound, offering a promising therapeutic option for patients suffering from these conditions.
Career Highlights
Throughout his career, Ueda has worked with prominent organizations such as Japan Tobacco Inc. and Kyoto University. His experience in these institutions has allowed him to refine his research and contribute to advancements in medical science.
Collaborations
Ueda has collaborated with notable colleagues, including Takafumi Kurimoto and Mutsuyoshi Matsushita. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his inventions.
Conclusion
Yoshifumi Ueda's innovative work in developing therapeutic agents showcases his commitment to improving healthcare solutions. His contributions to the field of pharmaceuticals are significant and continue to influence medical research and treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
